Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
about
Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation.Patterns and Outcomes Associated with Patient Migration for Liver Transplantation in the United StatesImpact of MELD Allocation System on Waiting List and Early Post-Liver Transplant Mortality.TIPE2 mRNA Level in PBMCs Serves as a Novel Biomarker for Predicting Short-Term Mortality of Acute-on-Chronic Hepatitis B Liver Failure: A Prospective Single-Center Study.Fair is fair: We must re-allocate livers for transplantCOMPARATIVE STUDY ON LIVER TRANSPLANTATION WITH AND WITHOUT HEPATOCELLULAR CARCINOMA WITH CIRRHOSIS: ANALYSIS OF MELD, WAITING TIME AND SURVIVAL.Patient-reported outcomes in liver transplant recipients with hepatocellular carcinoma.Model for end-stage liver disease score and MELD exceptions: 15 years later.Advanced chronic liver disease in the last year of life: a mixed methods study to understand how care in a specialist liver unit could be improved.Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient.Attitudes and barriers to the use of DCD livers: Comparison of a U.S. transplant center survey to the United Network for Organ Sharing data.Impact of hepatitis C virus infection on health-related quality of life before and after liver transplantation: a multidisciplinary point of view.Geographic variation in liver transplantation persists despite implementation of Share35.Projections in donor organs available for liver transplantation in the United States: 2014-2025.Transplant-related survival benefit should influence prioritization for liver transplantation especially in patients with hepatocellular carcinoma.Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease.Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.Disparities in Eurotransplant liver transplantation waitlist outcome between patients with and without exceptional MELD.Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States.Poor Performance Status Is Associated With Increased Mortality in Patients With Cirrhosis.Plasma interleukin-10 predicts short-term mortality of acute-on-chronic hepatitis B liver failure.Close observation versus upfront treatment in hepatocellular carcinoma: are the exception points worth the risk?Rising Rates of Hepatocellular Carcinoma Leading to Liver Transplantation in Baby Boomer Generation with Chronic Hepatitis C, Alcohol Liver Disease, and Nonalcoholic Steatohepatitis-Related Liver Disease.Optimal timing for hepatitis C antiviral therapy in the peritransplant period?How can we improve prioritization for liver transplantation in patients with hepatocellular carcinoma?Model for end-stage liver disease exceptions: A common problem.First-Degree Living-Related Donor Liver Transplantation in Autoimmune Liver Diseases.
P2860
Q35715908-C72A0622-1F08-454C-92D9-E40F5662C8ECQ35808168-D863B651-3612-48C6-81D7-E2A173F65CEDQ36051596-D4E970E8-8A65-4D3A-9D1E-E6E535734F6AQ36195966-DD568FB0-F632-42A3-9E38-79C3CC1C0E1EQ36337277-63407DE0-DCBD-4BC4-90BA-FD10AAA9AF7AQ36852128-E58D3268-2BB3-46F5-B29D-BD2F8BAA9DFAQ37611108-86890DB9-B8B3-4871-94F6-29E586846EB0Q38504284-7D43D80C-9C6E-4A44-81A9-F1104520A114Q38603154-A0493707-4092-4570-98F5-FD295368B4E5Q38604896-19FEB17B-C62E-4854-99E8-CEEC0698C078Q38611740-46E3BC9D-4519-42D5-B9B8-837022622BC7Q38653173-7777FF42-2BEC-4D64-BA5D-D1302A58CA8FQ38730876-F2F89AE6-23CE-4680-BBD5-73F0FC0FB4D5Q39021263-326AEE7B-DD04-403C-B801-11B612CDFE57Q39049983-90C24954-6732-4A78-8429-5EA1DC1D5F8DQ39067623-2A1BD8AB-74D9-4D95-B69D-86B54B9881AFQ39635570-E50D6E6E-EC6D-4D8F-970A-F007B8AE1850Q39652155-44D1FBA5-A23C-4F22-A4BB-FBD07CBA5AA9Q40145699-90BB3E02-1849-42C4-A344-732E549266A5Q40302269-F37411F7-47F9-4410-B729-1447D36ED902Q40817165-0D50F29C-3C8B-4D1A-929F-04150069A76FQ40821445-C9733512-D868-4E44-87C9-D00852B5D4A0Q41698350-F7E439D3-46B5-4610-A70F-ADDB52CCF472Q41929220-EDD99A7A-67B1-40F9-9AA6-6CD66C1B10A9Q47753414-4068A49E-38D9-481D-8646-689EB30C934EQ48044783-E44135B2-9A69-4B73-AF04-33AB5C98F6FDQ48180047-46ABA0E9-05B5-4686-9D13-70B84C1A1994Q53120479-BFA48A72-4229-4FFE-8967-82155967DD92
P2860
Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Excess mortality on the liver ...... iver Disease (MELD) inflation.
@ast
Excess mortality on the liver ...... iver Disease (MELD) inflation.
@en
type
label
Excess mortality on the liver ...... iver Disease (MELD) inflation.
@ast
Excess mortality on the liver ...... iver Disease (MELD) inflation.
@en
prefLabel
Excess mortality on the liver ...... iver Disease (MELD) inflation.
@ast
Excess mortality on the liver ...... iver Disease (MELD) inflation.
@en
P2093
P2860
P356
P1433
P1476
Excess mortality on the liver ...... Liver Disease (MELD) inflation
@en
P2093
Carl Lansing Berg
Curtis Kent Argo
Neeral Lalit Shah
Patrick Grant Northup
Shawn Joseph Pelletier
P2860
P304
P356
10.1002/HEP.27283
P407
P577
2014-10-29T00:00:00Z